Reports Q3 revenue $13.54M, consensus $12.68M. “Our innovative epinephrine prodrug platform remains the cornerstone of our development strategy,” said Daniel Barber, president and CEO of Aquestive. “We’ve reached a significant milestone with the clinical development program for Anaphylm, our groundbreaking oral epinephrine treatment for severe allergic reactions, including anaphylaxis. With our adult supportive studies now complete, we are preparing for our pre-NDA meeting for Anaphylm with the FDA scheduled for this quarter. Moreover, AQST-108, our promising pipeline candidate, is progressing towards a pre-IND meeting this quarter, setting the stage for a potential Phase 2a study in alopecia areata next year, subject to FDA alignment. On the commercial front, we successfully expanded Libervant’s market presence, deploying a dedicated sales force and securing nationwide reimbursement coverage, positioning us for continued growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AQST:
- Aquestive Therapeutics Optimistic Financial and Strategic Outlook
- Aquestive Therapeutics, Inc. (AQST) Q3 Earnings Cheat Sheet
- Aquestive to present subsequent analysis of data from Anaphylm study
- Aquestive announces primary, secondary endpoints met in OAS challenge study
- Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
